Vistagen Therapeutics Inc. (VTGN)
NASDAQ: VTGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VTGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.56M
- EPS (TTM)
- -$1.36
- Dividend yield
- None
- 52-week range
- 0.16 – 5.14
- Day range
- 0.1635 – 0.1915
- Volume / Avg
- 908.86K / 10.30M
- Beta
- —
- Shares outstanding
- 46.19M
52-week range
VTGN stock today
On Nov 20, VTGN ended the session at $0.1636, shedding $0.023 (12.33%), versus the S&P 500's 3.70% decline. Trading was light, with 908.86K shares changing hands, about 9% of the average daily volume. Shares are 96.8% below their 52-week high of $5.14, set on Nov 24, 2025 and 2.2% above the 52-week low of $0.16, near the bottom of the past year's range.
VTGN is down 75.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 96.4%. Vistagen Therapeutics has posted a net loss over the last twelve months (EPS of -$1.36), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Vistagen Therapeutics
Company profileVistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Shawn K. Singh J.D.
- Headquarters
- South San Francisco, CA
- Employees
- 41
- Website
- vistagen.com
Financial highlights
Full financialsIn fiscal 2026, Vistagen Therapeutics generated $1.3 million in revenue, up 161.1% from fiscal 2025. Vistagen Therapeutics reported a net loss of $69.7 million, compared with a loss of $51.4 million a year earlier. Operating margin was -5683.7%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $1.27M | $486.00K | $1.06M | $-227.00K | $1.11M |
| Growth | +161.11% | -54.32% | +568.72% | -120.47% | +1.79% |
| Net income | $-69.69M | $-51.42M | $-29.36M | $-59.25M | $-47.76M |
| EPS (diluted) | $-1.83 | $-1.67 | $-1.52 | $-8.51 | — |
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$1.00+511.25%
- Strong buy 0
- Buy 0
- Hold 4
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.24 vs $-0.37
- Surprise
- +35.14%
VTGN news
All VTGN news- Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate UpdateGlobeNewswire
- Vistagen Therapeutics, Inc. Announces Regulatory Update Following Type C Meeting with FDA on Phase 3 Development of FasedienolNasdaqVTGN, BRK.B
- Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety DisorderGlobeNewswire
- Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development ProgramsGlobeNewswire
Vistagen Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RKTORocket One Inc. | 0.297 | +5.24% | $7.39M | vs VTGN |
| PHIOPhio Pharmaceuticals Corp. | 0.656 | -8.25% | $7.84M | vs VTGN |
| IMRNImmuron Limited ADR | 0.8998 | +5.80% | $7.26M | vs VTGN |
| CLRBCellectar Biosciences Inc. | 0.797 | -11.50% | $8.00M | vs VTGN |
| DAREDare Bioscience Inc. | 0.4074 | -9.87% | $8.01M | vs VTGN |
| CVKDCadrenal Therapeutics Inc. | 1.70 | +0.59% | $7.01M | vs VTGN |
| ENSCEnsysce Biosciences Inc. | 0.36 | -0.17% | $7.00M | vs VTGN |
| TCRTAlaunos Therapeutics Inc. | 1.66 | +3.75% | $6.99M | vs VTGN |
Indexes, lists and sector
Vistagen Therapeutics stock FAQ
What is Vistagen Therapeutics's stock price today?
VTGN last traded at $0.1636 as of Nov 20, 4:00 PM EST, down 12.33% on the day. Prices are delayed at least 15 minutes.
Does Vistagen Therapeutics pay a dividend?
No. Vistagen Therapeutics does not currently pay a regular cash dividend.
Who is Vistagen Therapeutics's CEO?
Mr. Shawn K. Singh J.D. is the chief executive officer of Vistagen Therapeutics Inc., which has about 41 employees.
Has VTGN ever split its stock?
Yes. The most recent VTGN stock split was a 1-for-30 split on Jun 7, 2023, one of 2 splits on record.
What is the VTGN 52-week high?
The 52-week high for VTGN is $5.14 and the 52-week low is $0.16. The stock is currently 96.8% below its high.